These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 18408735)

  • 21. Repression of the transcription factor Th-POK by Runx complexes in cytotoxic T cell development.
    Setoguchi R; Tachibana M; Naoe Y; Muroi S; Akiyama K; Tezuka C; Okuda T; Taniuchi I
    Science; 2008 Feb; 319(5864):822-5. PubMed ID: 18258917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses.
    Volpe E; Servant N; Zollinger R; Bogiatzi SI; Hupé P; Barillot E; Soumelis V
    Nat Immunol; 2008 Jun; 9(6):650-7. PubMed ID: 18454150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cascading suppression of transcriptional silencers by ThPOK seals helper T cell fate.
    Muroi S; Naoe Y; Miyamoto C; Akiyama K; Ikawa T; Masuda K; Kawamoto H; Taniuchi I
    Nat Immunol; 2008 Oct; 9(10):1113-21. PubMed ID: 18776907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells.
    Guo Z; Zheng C; Chen Z; Gu D; Du W; Ge J; Han Z; Yang R
    Eur J Immunol; 2009 Oct; 39(10):2840-9. PubMed ID: 19637224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets.
    Chatila TA; Li N; Garcia-Lloret M; Kim HJ; Nel AE
    J Allergy Clin Immunol; 2008 Apr; 121(4):812-23; quiz 824-5. PubMed ID: 18395547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4-CD8 lineage commitment: an inside view.
    Kappes DJ; He X; He X
    Nat Immunol; 2005 Aug; 6(8):761-6. PubMed ID: 16034433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-17-producing T cells in lung immunity and inflammation.
    Nembrini C; Marsland BJ; Kopf M
    J Allergy Clin Immunol; 2009 May; 123(5):986-94; quiz 995-6. PubMed ID: 19410688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
    Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
    J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation and function of proinflammatory TH17 cells.
    Martinez GJ; Nurieva RI; Yang XO; Dong C
    Ann N Y Acad Sci; 2008 Nov; 1143():188-211. PubMed ID: 19076351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
    Leveque L; Deknuydt F; Bioley G; Old LJ; Matsuzaki J; Odunsi K; Ayyoub M; Valmori D
    J Immunother; 2009; 32(2):101-8. PubMed ID: 19238008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Th17 cells: a new paradigm for cutaneous inflammation.
    Asarch A; Barak O; Loo DS; Gottlieb AB
    J Dermatolog Treat; 2008; 19(5):259-66. PubMed ID: 18629676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.
    Huber M; Heink S; Grothe H; Guralnik A; Reinhard K; Elflein K; Hünig T; Mittrücker HW; Brüstle A; Kamradt T; Lohoff M
    Eur J Immunol; 2009 Jul; 39(7):1716-25. PubMed ID: 19544308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune suppressive activity and lack of T helper differentiation are differentially regulated in natural regulatory T cells.
    Zeng WP; Chang C; Lai JJ
    J Immunol; 2009 Sep; 183(6):3583-90. PubMed ID: 19710452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impairment of T helper and T regulatory cell responses at birth.
    Schaub B; Liu J; Schleich I; Höppler S; Sattler C; von Mutius E
    Allergy; 2008 Nov; 63(11):1438-47. PubMed ID: 18925880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.
    Yadav M; Goetzl EJ
    Ann N Y Acad Sci; 2008 Nov; 1144():83-9. PubMed ID: 19076367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T helper cell effector fates--who, how and where?
    Reinhardt RL; Kang SJ; Liang HE; Locksley RM
    Curr Opin Immunol; 2006 Jun; 18(3):271-7. PubMed ID: 16617008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of IL-23-Th17 cell axis in allergic airway inflammation.
    Wakashin H; Hirose K; Iwamoto I; Nakajima H
    Int Arch Allergy Immunol; 2009; 149 Suppl 1():108-12. PubMed ID: 19494515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo.
    Sonderegger I; Kisielow J; Meier R; King C; Kopf M
    Eur J Immunol; 2008 Jul; 38(7):1833-8. PubMed ID: 18546146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.